|
業務類別
|
Biotechnology |
|
業務概覽
|
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liverfibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
| 公司地址
| 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 567-7770 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.gyretx.com |
| 員工數量
| 625 |
| Mr. Ping Zhang |
Executive Chairman of the Board and Interim Chief Executive Officer |
美元 189.78K |
27/04/2026 |
| Mr. Weiguo Ye |
Chief Operating Officer |
美元 196.95K |
27/04/2026 |
| Mr. Songjiang Ma |
Director and President |
-- |
02/03/2026 |
| Ms. Ruoyu Chen |
Chief Financial Officer and Principal Accounting Officer |
美元 250.00K |
27/04/2026 |
|
|
| Mr. Ping Zhang |
Executive Chairman of the Board and Interim Chief Executive Officer |
27/04/2026 |
| Dr. Ying Luo, PhD |
Director |
27/04/2026 |
| Mr. Rodney L. Nussbaum |
Independent Director |
27/04/2026 |
| Dr. Gordon G. Carmichael, PhD |
Independent Director |
27/04/2026 |
| Dr. Renate Parry, PhD |
Independent Director |
27/04/2026 |
| Mr. Songjiang Ma |
Director and President |
02/03/2026 |
| Dr. David M. Epstein, PhD |
Independent Director |
27/04/2026 |
| Mr. Thomas Eastling |
Director |
02/03/2026 |
| Dr. Dan Weng, M.D. |
Independent Director |
27/04/2026 |
|
|
|
|
